These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22084957)

  • 1. Cost-effectiveness analysis of valsartan versus losartan and the effect of switching.
    Baker TM; Goh J; Johnston A; Falvey H; Brede Y; Brown RE
    J Med Econ; 2012; 15(2):253-60. PubMed ID: 22084957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L; Iannazzo S; Zaniolo O
    Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension.
    Signorovitch J; Zhang J; Wu EQ; Latremouille-Viau D; Yu AP; Dastani HB; Kahler KH
    Curr Med Res Opin; 2010 Apr; 26(4):849-60. PubMed ID: 20141381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece.
    Maniadakis N; Ekman M; Fragoulakis V; Papagiannopoulou V; Yfantopoulos J
    Eur J Health Econ; 2011 Jun; 12(3):253-61. PubMed ID: 20411401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
    Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
    Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors.
    Taylor M; Scuffham PA; Chaplin S; Papo NL
    Value Health; 2009 Jun; 12(4):459-65. PubMed ID: 19192258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
    Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolutionary cost analysis of valsartan initiation among patients with hypertension: a time series approach.
    Sun P; Chang J; Zhang J; Kahler KH
    J Med Econ; 2012; 15(1):8-18. PubMed ID: 22011107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy.
    Baser O; Andrews LM; Wang L; Xie L
    J Med Econ; 2011; 14(5):576-83. PubMed ID: 21728914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen.
    Belsey JD
    Curr Med Res Opin; 2008 Feb; 24(2):581-9. PubMed ID: 18198012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost-effectiveness of treatment of high blood pressure with losartan in Denmark].
    Keiding H; Hildebrandt P; Burke T; Carides GW
    Ugeskr Laeger; 2006 Oct; 168(42):3623-6. PubMed ID: 17069726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of valsartan for treatment of hypertension: patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study).
    Van der Niepen P; Woestenburg A; Brié H; Vancayzeele S; MacDonald K; Denhaerynck K; Lee C; Hermans C; Abraham I
    Ann Pharmacother; 2009 May; 43(5):849-61. PubMed ID: 19351876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
    McInnes G; Burke TA; Carides G
    J Hum Hypertens; 2006 Jan; 20(1):51-8. PubMed ID: 16357874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.
    Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
    Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28974512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial.
    Ohsfeldt RL; Olsson AG; Jensen MM; Gandhi SK; Paulsson T
    J Med Econ; 2012; 15(1):125-33. PubMed ID: 22050473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy.
    Malesker MA; Hilleman DE
    Manag Care; 2010 Jul; 19(7):36-42. PubMed ID: 20672530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
    Ekman M; Bienfait-Beuzon C; Jackson J
    J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.